Daniel A. Rushing, MD | Authors

Articles

Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC

July 02, 2000

This phase I/II nonrandomized, open-label study was designed to assess the safety and benefit of sequencing irinotecan (Camptosar, CPT-11) plus paclitaxel (Taxol) immediately after cisplatin (Platinol)/etoposide (VePesid,